David Scott Miller, Professor and Chief of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, leads the team of gynecologic oncologists at UT Southwestern. He is Medical Director for the Division's practice at the NCI-designated Harold C. Simmons Cancer Center.
Dr. Miller also serves as principal investigator for the National Cancer Institute’s Gynecologic Oncology Group program at UT Southwestern and participates in the cancer treatment protocols developed by that organization.
A graduate of the University of Oklahoma College of Medicine, Dr. Miller completed his residency in obstetrics and gynecology at the Hospital of the Medical College of Pennsylvania. After residency, he pursued a reproductive endocrinology fellowship at the University of California-San Diego and a gynecologic oncology fellowship at Stanford University Medical Center. Before joining the faculty at UT Southwestern in 1991, he practiced gynecologic oncology at Northwestern University Medical School in Chicago.
Widely-known as an authority on cancers of the female reproductive system, Dr. Miller is board certified in both obstetrics and gynecology and gynecologic oncology. He serves as an examiner for the American Board of Obstetrics and Gynecology, where he participates in the oral examination of physicians seeking certification as specialists in gynecologic oncology. He is a member of the Society of Gynecologic Oncologists, American Society of Clinical Oncology, American Congress of Obstetricians and Gynecologists, and the American College of Surgeons.
Dr. Miller believes the gynecologic oncology team’s strength comes from its collaborative approach to health care and commitment to search for the best treatment options for women with cancer of the reproductive system. This approach goes beyond treatment of the cancer itself to include the patient’s nutrition and pain management as well as psychological and social adjustments.
- Medical School
- University of Oklahoma at Tulsa (1977)
- Medical College of Pennsylvania (1978), Obstetrics & Gynecology
- Medical College of Pennsylvania (1981), Obstetrics & Gynecology
- University of California at San Diego (1982), Gynecologic Oncology
- Stanford University Hospital (1985), Gynecologic Oncology
- Antineoplastic drug development
- Clinical trials
- Gynecologic Oncology
- Reconstructive pelvic surgery
- Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
- Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH J. Clin. Oncol. 2009 Jun 27 16 2686-91
- Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer.
- Miller DS, Fleming G, Randall ME J Natl Compr Canc Netw 2009 May 7 5 535-41
- Recent progress: gynecologic oncology group trials in uterine corpus tumors.
- King LP, Miller DS Rev Recent Clin Trials 2009 May 4 2 70-4
- Somatic LKB1 mutations promote cervical cancer progression.
- Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge JO, Wong KK, Castrillon DH PLoS ONE 2009 4 4 e5137
- Gynecologic oncology group trials in uterine corpus malignancies: recent progress.
- Miller DS, King LP J Gynecol Oncol 2008 Dec 19 4 218-22
- Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group
- Miller, D.S., Blessing, J.A., Bodurka, D.C., Bonebrake, A.J., Schorge, J.O. Gynecologic Oncology July 2008 110(1) 65-70
- Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
- Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO Gynecol. Oncol. 2008 Jul 110 1 65-70
- Implications of EGFR inhibition in ovarian cancer cell proliferation
- Bull Phelps, S.L., Schorge, J.O., Peyton, M.J., Shigematsu, H., Xiang, L.-L., Miller, D.S., Lea, J.S. Gynecologic Oncology June 2008 109(3) 411-7
- Implications of EGFR inhibition in ovarian cancer cell proliferation.
- Bull Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang LL, Miller DS, Lea JS Gynecol. Oncol. 2008 Jun 109 3 411-7
- Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix
- Bull-Phelps, S.L., Garner, E.I.O., Walsh, C.S., Gehrig, P.A., Miller, D.S., Schorge, J.O. Gynecologic Oncology November 2007 107 (2) 316-319
Honors & Awards
- Super Doctors in Texas - Oncology
Oncology; Obstetrics/Gynecology (2013)
- Top Doctor - Gynecologic Oncology / Gynecology
U.S. News and World Report (2013)
- D Best - Gynecological Oncology
D Magazine Best Doctors 2010, 2011 (2012)
- Texas Super Doctors
Texas Monthly (2011)
- National Faculty Award
Council on Resident Education in Obstetrics & Gynecology (2000)
- Senior Residents Award for Outstanding Faculty Teacher
Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center at Dallas (2000)
- First Prize Scientific Paper Award
American College of Obstetricians & Gynecologists, 39th Annual Meeting (1991)
- D Best Doctor - Gynecological Oncology
D Magazine - 2012, 2011, 2010
- American College of Obstetricians & Gynecologists
- American College of Surgeons
- American Society of Clinical Oncology
- Gynecologic Oncology Group
- Society of Gynecologic Oncology